# Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia

> **NCT07498647** · PHASE2 · NOT_YET_RECRUITING · sponsor: **BioRay Pharmaceutical Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Gout and Hyperuricemia

## Interventions

- **DRUG:** BR2251
- **DRUG:** Febuxostat

## Key facts

- **NCT ID:** NCT07498647
- **Lead sponsor:** BioRay Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-11-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498647, "Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07498647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*